Joachim Labenz1, Herbert Koop, Andrea Tannapfel, Ralf Kiesslich, Arnulf H Hölscher. 1. Department of Internal Medicine and Gastroenterology, Diakonie Klinikum, Jung-Stilling Hospital, Siegen, Department of General Practice, Internal Medicine and Gastroenterology, HELIOS Hospital Berlin-Buch, Institute of Pathology, Ruhr-University Bochum, Dr.-Horst-Schmidt-Kliniken, Wiesbaden, Department of General, Visceral and Cancer Surgery, University of Cologne.
Abstract
BACKGROUND: Roughly 3000 new cases of Barrett's carcinoma arise in Germany each year. In view of recent advances in the epidemiology, diagnosis, and treatment of this disease, an update of the clinical recommendations is in order. METHODS: This review is based on selected relevant publications, including current reviews, meta-analyses, and guidelines. RESULTS: The risk of progression of Barrett's esophagus to carcinoma lies between 0.10% and 0.15% per year. Risk factors for progression include male sex, age over 50 years, obesity, longstanding and frequent reflux symptoms, smoking, length of the Barrett's esophagus, and intraepithelial neoplasia. Well-differentiated carcinomas that are confined to the esophageal mucosa can be resected endoscopically with a cure rate above 90%. For more advanced, but still locally confined tumors, surgical resection is the treatment of choice. In stages cT3/4, the prognosis can be improved with neo-adjuvant chemo - therapy or combined radiotherapy and chemotherapy. Metastatic Barrett's carcinoma can be treated by endoscopic, chemotherapeutic, radiotherapeutic, and palliative methods. CONCLUSION: Early carcinoma can often be cured by endoscopic resection. Locally advanced carcinoma calls for multimodal treatment. Current research focuses on means of preventing the progression of Barrett's esophagus, the scope of applicability of endoscopic techniques, and the optimization of multimodal treatment strategies for advanced disease.
BACKGROUND: Roughly 3000 new cases of Barrett's carcinoma arise in Germany each year. In view of recent advances in the epidemiology, diagnosis, and treatment of this disease, an update of the clinical recommendations is in order. METHODS: This review is based on selected relevant publications, including current reviews, meta-analyses, and guidelines. RESULTS: The risk of progression of Barrett's esophagus to carcinoma lies between 0.10% and 0.15% per year. Risk factors for progression include male sex, age over 50 years, obesity, longstanding and frequent reflux symptoms, smoking, length of the Barrett's esophagus, and intraepithelial neoplasia. Well-differentiated carcinomas that are confined to the esophageal mucosa can be resected endoscopically with a cure rate above 90%. For more advanced, but still locally confined tumors, surgical resection is the treatment of choice. In stages cT3/4, the prognosis can be improved with neo-adjuvant chemo - therapy or combined radiotherapy and chemotherapy. Metastatic Barrett's carcinoma can be treated by endoscopic, chemotherapeutic, radiotherapeutic, and palliative methods. CONCLUSION: Early carcinoma can often be cured by endoscopic resection. Locally advanced carcinoma calls for multimodal treatment. Current research focuses on means of preventing the progression of Barrett's esophagus, the scope of applicability of endoscopic techniques, and the optimization of multimodal treatment strategies for advanced disease.
Authors: H Koop; K H Fuchs; J Labenz; P Lynen Jansen; H Messmann; S Miehlke; W Schepp; T G Wenzl Journal: Z Gastroenterol Date: 2014-11-12 Impact factor: 2.000
Authors: Lori A Fischbach; David Y Graham; Jennifer R Kramer; Massimo Rugge; Gordana Verstovsek; Paola Parente; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Anna Kolpachi; Swapna Gupta; Marcelo F Vela; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Hashem B El Serag Journal: Am J Gastroenterol Date: 2014-01-14 Impact factor: 10.864
Authors: Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta Journal: Lancet Date: 2012-05-01 Impact factor: 79.321
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Jo-Etienne Abela; James J Going; John F Mackenzie; Margaret McKernan; Sylvia O'Mahoney; Robert C Stuart Journal: Am J Gastroenterol Date: 2008-03-26 Impact factor: 10.864
Authors: Stephanie A Navarro Silvera; Susan T Mayne; Marilie D Gammon; Thomas L Vaughan; Wong-Ho Chow; Joel A Dubin; Robert Dubrow; Janet L Stanford; A Brian West; Heidrun Rotterdam; William J Blot; Harvey A Risch Journal: Ann Epidemiol Date: 2013-10-18 Impact factor: 6.996